<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02626663</url>
  </required_header>
  <id_info>
    <org_study_id>RSRB00059370</org_study_id>
    <nct_id>NCT02626663</nct_id>
  </id_info>
  <brief_title>The Role of Microparticles as a Biomarker</brief_title>
  <official_title>The Role of Microparticles as a Biomarker in Distinguishing Between Thrombotic Thrombocytopenic Purpura (TTP) and Atypical Hemolytic Uremic Syndrome (aHUS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to characterize MPs in aHUS and TTP both at the onset and
      throughout treatment. The investigators believe that the number, size, and cell origin of MPs
      will differ between these two diseases. The hypothesis is that endothelial derived MPs will
      be higher in number and comprise a larger portion of the MP population in aHUS and that
      platelet MPs will comprise a larger number and greater proportion of MPs in TTP. The
      investigators believe that MP identity and number can be used to reliably differentiate
      between aHUS and TTP at disease onset.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Microparticle/Nanoparticle number (an absolute number)</measure>
    <time_frame>an average of 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Microparticle/Nanoparticle size (in nanometers or micrometers)</measure>
    <time_frame>an average of 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Microparticle/Nanoparticle identity (identity of cell type from which they are derived)</measure>
    <time_frame>an average of 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidities</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atypical Hemolytic Uremic Syndrome</condition>
  <condition>Thrombotic Thrombocytopenic Purpura</condition>
  <condition>Microparticles</condition>
  <condition>Microangiopathic Hemolytic Anemia</condition>
  <arm_group>
    <arm_group_label>aHUS</arm_group_label>
    <description>atypical Hemolytic Uremic Syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TTP</arm_group_label>
    <description>Thrombotic thrombocytopenic purpura</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAHA</arm_group_label>
    <description>other microangiopathic hemolytic anemias</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      platelet poor plasma samples will be retained. These samples will contain Microparticles and
      nanoparticles as well as microRNA.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting with Microangiopathic Hemolytic Anemias (MAHA), TTP, and/or aHUS are
        eligible.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with MAHA, TTP, and/or aHUS

        Exclusion Criteria:

          -  Prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Schmidt, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>December 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2015</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Amy Schmidt</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
    <mesh_term>Azotemia</mesh_term>
    <mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
    <mesh_term>Purpura, Thrombotic Thrombocytopenic</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

